{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T16:25:05Z","timestamp":1782059105637,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K07242"],"award-info":[{"award-number":["21K07242"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H04808"],"award-info":[{"award-number":["21H04808"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04316-z","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T06:58:16Z","timestamp":1770447496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["CAR-T cells co-expressing IL-7 and CCL19 promote epitope spreading to enhance antitumor immunity"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7524-2886","authenticated-orcid":false,"given":"Keishi","family":"Adachi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1519-893X","authenticated-orcid":false,"given":"Yukimi","family":"Sakoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3098-2565","authenticated-orcid":false,"given":"Tsuneyasu","family":"Kaisho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2616-1665","authenticated-orcid":false,"given":"Koji","family":"Tamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"key":"4316_CR1","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immunotherapy for human cancer. Science 359:1361\u20131365. https:\/\/doi.org\/10.1126\/science.aar6711","journal-title":"Science"},{"key":"4316_CR2","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","volume":"33","author":"KK Patel","year":"2025","unstructured":"Patel KK, Tariveranmoshabad M, Kadu S, Shobaki N, June C (2025) From concept to cure: the evolution of CAR-T cell therapy. Mol Ther 33:2123\u20132140. https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.005","journal-title":"Mol Ther"},{"key":"4316_CR3","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1111\/cas.15552","volume":"113","author":"K Adachi","year":"2022","unstructured":"Adachi K, Tamada K (2022) Paving the road to make chimeric antigen receptor-T-cell therapy effective against solid tumors. Cancer Sci 113:4020\u20134029. https:\/\/doi.org\/10.1111\/cas.15552","journal-title":"Cancer Sci"},{"key":"4316_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0758-x","volume":"12","author":"J Wei","year":"2019","unstructured":"Wei J, Han X, Bo J, Han W (2019) Target selection for CAR-T therapy. J Hematol Oncol 12:62. https:\/\/doi.org\/10.1186\/s13045-019-0758-x","journal-title":"J Hematol Oncol"},{"key":"4316_CR5","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18:843\u2013851. https:\/\/doi.org\/10.1038\/mt.2010.24","journal-title":"Mol Ther"},{"key":"4316_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, Abou-El-Enein M (2023) Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol 20:49\u201362. https:\/\/doi.org\/10.1038\/s41571-022-00704-3","journal-title":"Nat Rev Clin Oncol"},{"key":"4316_CR7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Swanton C (2017) Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168:613\u2013628. https:\/\/doi.org\/10.1016\/j.cell.2017.01.018","journal-title":"Cell"},{"key":"4316_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051075","author":"S Kailayangiri","year":"2020","unstructured":"Kailayangiri S, Altvater B, Wiebel M, Jamitzky S, Rossig C (2020) Overcoming heterogeneity of antigen expression for effective CAR T cell targeting of cancers. Cancers. https:\/\/doi.org\/10.3390\/cancers12051075","journal-title":"Cancers"},{"key":"4316_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","author":"DM O'Rourke","year":"2017","unstructured":"O\u2019Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV (2017) A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaa0984","journal-title":"Sci Transl Med"},{"key":"4316_CR10","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/jci83416","volume":"126","author":"M Hegde","year":"2016","unstructured":"Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N (2016) Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape. J Clin Invest 126:3036\u20133052. https:\/\/doi.org\/10.1172\/jci83416","journal-title":"J Clin Invest"},{"key":"4316_CR11","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.omto.2022.02.012","volume":"24","author":"N Muhammad","year":"2022","unstructured":"Muhammad N, Wang R, Li W, Zhang Z, Chang Y, Hu Y, Zhao J, Zheng X, Mao Q, Xia H (2022) A novel TanCAR targeting IL13R\u03b12 and EphA2 for enhanced glioblastoma therapy. Mol Ther Oncolytics 24:729\u2013741. https:\/\/doi.org\/10.1016\/j.omto.2022.02.012","journal-title":"Mol Ther Oncolytics"},{"key":"4316_CR12","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1158\/1078-0432.ccr-12-1449","volume":"18","author":"K Tamada","year":"2012","unstructured":"Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z, Davila E (2012) Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res 18:6436\u20136445. https:\/\/doi.org\/10.1158\/1078-0432.ccr-12-1449","journal-title":"Clin Cancer Res"},{"key":"4316_CR13","doi-asserted-by":"publisher","first-page":"E459","DOI":"10.1073\/pnas.1524155113","volume":"113","author":"DT Rodgers","year":"2016","unstructured":"Rodgers DT, Mazagova M, Hampton EN, Cao Y, Ramadoss NS, Hardy IR, Schulman A, Du J, Wang F, Singer O, Ma J, Nunez V, Shen J, Woods AK, Wright TM, Schultz PG, Kim CH, Young TS (2016) Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A 113:E459-468. https:\/\/doi.org\/10.1073\/pnas.1524155113","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4316_CR14","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","volume":"173","author":"JH Cho","year":"2018","unstructured":"Cho JH, Collins JJ, Wong WW (2018) Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173:1426-1438.e1411. https:\/\/doi.org\/10.1016\/j.cell.2018.03.038","journal-title":"Cell"},{"key":"4316_CR15","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ccell.2019.10.006","volume":"36","author":"I Etxeberria","year":"2019","unstructured":"Etxeberria I, Bola\u00f1os E, Quetglas JI, Gros A, Villanueva A, Palomero J, S\u00e1nchez-Paulete AR, Piulats JM, Matias-Guiu X, Olivera I, Ochoa MC, Labiano S, Garasa S, Rodriguez I, Vidal A, Manche\u00f1o U, Herv\u00e1s-Stubbs S, Azpilikueta A, Otano I, Aznar MA, Sanmamed MF, Inog\u00e9s S, Berraondo P, Teijeira \u00c1, Melero I (2019) Intratumor adoptive transfer of IL-12 mRNA transiently engineered antitumor CD8(+) T cells. Cancer Cell 36:613-629.e617. https:\/\/doi.org\/10.1016\/j.ccell.2019.10.006","journal-title":"Cancer Cell"},{"key":"4316_CR16","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","volume":"21","author":"J Lai","year":"2020","unstructured":"Lai J, Mardiana S, House IG, Sek K, Henderson MA, Giuffrida L, Chen AXY, Todd KL, Petley EV, Chan JD, Carrington EM, Lew AM, Solomon BJ, Trapani JA, Kedzierska K, Evrard M, Vervoort SJ, Waithman J, Darcy PK, Beavis PA (2020) Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nat Immunol 21:914\u2013926. https:\/\/doi.org\/10.1038\/s41590-020-0676-7","journal-title":"Nat Immunol"},{"key":"4316_CR17","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41551-022-00875-5","volume":"6","author":"C Jin","year":"2022","unstructured":"Jin C, Ma J, Ramachandran M, Yu D, Essand M (2022) CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers. Nat Biomed Eng 6:830\u2013841. https:\/\/doi.org\/10.1038\/s41551-022-00875-5","journal-title":"Nat Biomed Eng"},{"key":"4316_CR18","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1200\/jco.2015.65.5142","volume":"34","author":"AG Chapuis","year":"2016","unstructured":"Chapuis AG, Roberts IM, Thompson JA, Margolin KA, Bhatia S, Lee SM, Sloan HL, Lai IP, Farrar EA, Wagener F, Shibuya KC, Cao J, Wolchok JD, Greenberg PD, Yee C (2016) T-cell therapy using interleukin-21-primed cytotoxic T-cell lymphocytes combined with cytotoxic T-cell lymphocyte antigen-4 blockade results in long-term cell persistence and durable tumor regression. J Clin Oncol 34:3787\u20133795. https:\/\/doi.org\/10.1200\/jco.2015.65.5142","journal-title":"J Clin Oncol"},{"key":"4316_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.Cir-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH (2014) Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2:112\u2013120. https:\/\/doi.org\/10.1158\/2326-6066.Cir-13-0170","journal-title":"Cancer Immunol Res"},{"key":"4316_CR20","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K (2018) IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol 36:346\u2013351. https:\/\/doi.org\/10.1038\/nbt.4086","journal-title":"Nat Biotechnol"},{"key":"4316_CR21","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1007\/s00262-021-02853-3","volume":"70","author":"S Goto","year":"2021","unstructured":"Goto S, Sakoda Y, Adachi K, Sekido Y, Yano S, Eto M, Tamada K (2021) Enhanced anti-tumor efficacy of IL-7\/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models. Cancer Immunol Immunother 70:2503\u20132515. https:\/\/doi.org\/10.1007\/s00262-021-02853-3","journal-title":"Cancer Immunol Immunother"},{"key":"4316_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.Cir-14-0098","volume":"3","author":"H Matsushita","year":"2015","unstructured":"Matsushita H, Hosoi A, Ueha S, Abe J, Fujieda N, Tomura M, Maekawa R, Matsushima K, Ohara O, Kakimi K (2015) Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFN\u03b3-dependent cell-cycle arrest. Cancer Immunol Res 3:26\u201336. https:\/\/doi.org\/10.1158\/2326-6066.Cir-14-0098","journal-title":"Cancer Immunol Res"},{"key":"4316_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4049\/jimmunol.1200135","volume":"190","author":"LV Ly","year":"2013","unstructured":"Ly LV, Sluijter M, van der Burg SH, Jager MJ, van Hall T (2013) Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma. J Immunol 190:489\u2013496. https:\/\/doi.org\/10.4049\/jimmunol.1200135","journal-title":"J Immunol"},{"key":"4316_CR24","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1002\/eji.1830251013","volume":"25","author":"U Grohmann","year":"1995","unstructured":"Grohmann U, Bianchi R, Fioretti MC, Fallarino F, Binaglia L, Uyttenhove C, Van Pel A, Boon T, Puccetti P (1995) CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide. Eur J Immunol 25:2797\u20132802. https:\/\/doi.org\/10.1002\/eji.1830251013","journal-title":"Eur J Immunol"},{"key":"4316_CR25","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1002\/(sici)1521-4141(199812)28:12<4010::Aid-immu4010>3.0.Co;2-5","volume":"28","author":"D Br\u00e4ndle","year":"1998","unstructured":"Br\u00e4ndle D, Bilsborough J, R\u00fclicke T, Uyttenhove C, Boon T, den Van Eynde BJ (1998) The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. Eur J Immunol 28:4010\u20134019. https:\/\/doi.org\/10.1002\/(sici)1521-4141(199812)28:12%3c4010::Aid-immu4010%3e3.0.Co;2-5","journal-title":"Eur J Immunol"},{"key":"4316_CR26","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nature14001","volume":"515","author":"M Yadav","year":"2014","unstructured":"Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, Modrusan Z, Mellman I, Lill JR, Delamarre L (2014) Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515:572\u2013576. https:\/\/doi.org\/10.1038\/nature14001","journal-title":"Nature"},{"key":"4316_CR27","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1158\/1078-0432.Ccr-20-0305","volume":"26","author":"P Brossart","year":"2020","unstructured":"Brossart P (2020) The role of antigen spreading in the efficacy of immunotherapies. Clin Cancer Res 26:4442\u20134447. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-0305","journal-title":"Clin Cancer Res"},{"key":"4316_CR28","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1084\/jem.192.12.1685","volume":"192","author":"JM den Haan","year":"2000","unstructured":"den Haan JM, Lehar SM, Bevan MJ (2000) CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 192:1685\u20131696. https:\/\/doi.org\/10.1084\/jem.192.12.1685","journal-title":"J Exp Med"},{"key":"4316_CR29","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1084\/jem.20020161","volume":"195","author":"T Iyoda","year":"2002","unstructured":"Iyoda T, Shimoyama S, Liu K, Omatsu Y, Akiyama Y, Maeda Y, Takahara K, Steinman RM, Inaba K (2002) The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med 195:1289\u20131302. https:\/\/doi.org\/10.1084\/jem.20020161","journal-title":"J Exp Med"},{"key":"4316_CR30","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/intimm\/10.7.901","volume":"10","author":"R Yoshida","year":"1998","unstructured":"Yoshida R, Nagira M, Imai T, Baba M, Takagi S, Tabira Y, Akagi J, Nomiyama H, Yoshie O (1998) EBI1-ligand chemokine (ELC) attracts a broad spectrum of lymphocytes: activated T cells strongly up-regulate CCR7 and efficiently migrate toward ELC. Int Immunol 10:901\u2013910","journal-title":"Int Immunol"},{"key":"4316_CR31","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.4049\/jimmunol.162.7.3859","volume":"162","author":"SA Kellermann","year":"1999","unstructured":"Kellermann SA, Hudak S, Oldham ER, Liu YJ, McEvoy LM (1999) The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3 beta are potent chemoattractants for in vitro- and in vivo-derived dendritic cells. J Immunol 162:3859\u20133864","journal-title":"J Immunol"},{"key":"4316_CR32","doi-asserted-by":"publisher","first-page":"6071","DOI":"10.4049\/jimmunol.1202798","volume":"190","author":"C Yamazaki","year":"2013","unstructured":"Yamazaki C, Sugiyama M, Ohta T, Hemmi H, Hamada E, Sasaki I, Fukuda Y, Yano T, Nobuoka M, Hirashima T, Iizuka A, Sato K, Tanaka T, Hoshino K, Kaisho T (2013) Critical roles of a dendritic cell subset expressing a chemokine receptor, XCR1. J Immunol 190:6071\u20136082. https:\/\/doi.org\/10.4049\/jimmunol.1202798","journal-title":"J Immunol"},{"key":"4316_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1146\/annurev.immunol.16.1.111","volume":"16","author":"IS Grewal","year":"1998","unstructured":"Grewal IS, Flavell RA (1998) CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16:111\u2013135. https:\/\/doi.org\/10.1146\/annurev.immunol.16.1.111","journal-title":"Annu Rev Immunol"},{"key":"4316_CR34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.coi.2007.04.012","volume":"19","author":"ME Keir","year":"2007","unstructured":"Keir ME, Francisco LM, Sharpe AH (2007) PD-1 and its ligands in T-cell immunity. Curr Opin Immunol 19:309\u2013314. https:\/\/doi.org\/10.1016\/j.coi.2007.04.012","journal-title":"Curr Opin Immunol"},{"key":"4316_CR35","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","volume":"584","author":"ST Ferris","year":"2020","unstructured":"Ferris ST, Durai V, Wu R, Theisen DJ, Ward JP, Bern MD, Davidson JTt, Bagadia P, Liu T, Brise\u00f1o CG, Li L, Gillanders WE, Wu GF, Yokoyama WM, Murphy TL, Schreiber RD, Murphy KM (2020) cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity. Nature 584:624\u2013629. https:\/\/doi.org\/10.1038\/s41586-020-2611-3","journal-title":"Nature"},{"key":"4316_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0092-8674(94)90169-4","volume":"76","author":"KA Hogquist","year":"1994","unstructured":"Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR (1994) T cell receptor antagonist peptides induce positive selection. Cell 76:17\u201327. https:\/\/doi.org\/10.1016\/0092-8674(94)90169-4","journal-title":"Cell"},{"key":"4316_CR37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nbt0102-87","volume":"20","author":"T Nagai","year":"2002","unstructured":"Nagai T, Ibata K, Park ES, Kubota M, Mikoshiba K, Miyawaki A (2002) A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat Biotechnol 20:87\u201390. https:\/\/doi.org\/10.1038\/nbt0102-87","journal-title":"Nat Biotechnol"},{"key":"4316_CR38","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3389\/fimmu.2012.00214","volume":"3","author":"A Bachem","year":"2012","unstructured":"Bachem A, Hartung E, G\u00fcttler S, Mora A, Zhou X, Hegemann A, Plantinga M, Mazzini E, Stoitzner P, Gurka S, Henn V, Mages HW, Kroczek RA (2012) Expression of XCR1 characterizes the Batf3-dependent lineage of dendritic cells capable of antigen cross-presentation. Front Immunol 3:214. https:\/\/doi.org\/10.3389\/fimmu.2012.00214","journal-title":"Front Immunol"},{"key":"4316_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00035","volume":"6","author":"S Gurka","year":"2015","unstructured":"Gurka S, Hartung E, Becker M, Kroczek RA (2015) Mouse conventional dendritic cells can be universally classified based on the mutually exclusive expression of XCR1 and SIRP\u03b1. Front Immunol 6:35. https:\/\/doi.org\/10.3389\/fimmu.2015.00035","journal-title":"Front Immunol"},{"key":"4316_CR40","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1158\/1535-7163.Mct-21-0400","volume":"21","author":"Y Tokunaga","year":"2022","unstructured":"Tokunaga Y, Sasaki T, Goto S, Adachi K, Sakoda Y, Tamada K (2022) Enhanced antitumor responses of tumor antigen-specific TCR T cells genetically engineered to produce IL7 and CCL19. Mol Cancer Ther 21:138\u2013148. https:\/\/doi.org\/10.1158\/1535-7163.Mct-21-0400","journal-title":"Mol Cancer Ther"},{"key":"4316_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev.immunol.26.021607.090254","volume":"26","author":"GJ Randolph","year":"2008","unstructured":"Randolph GJ, Ochando J, Partida-S\u00e1nchez S (2008) Migration of dendritic cell subsets and their precursors. Annu Rev Immunol 26:293\u2013316. https:\/\/doi.org\/10.1146\/annurev.immunol.26.021607.090254","journal-title":"Annu Rev Immunol"},{"key":"4316_CR42","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1182\/blood.v97.4.1027","volume":"97","author":"E Chklovskaia","year":"2001","unstructured":"Chklovskaia E, Nissen C, Landmann L, Rahner C, Pfister O, Wodnar-Filipowicz A (2001) Cell-surface trafficking and release of flt3 ligand from T lymphocytes is induced by common cytokine receptor gamma-chain signaling and inhibited by cyclosporin A. Blood 97:1027\u20131034. https:\/\/doi.org\/10.1182\/blood.v97.4.1027","journal-title":"Blood"},{"key":"4316_CR43","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.1182\/blood-2008-08-176321","volume":"113","author":"TK Vogt","year":"2009","unstructured":"Vogt TK, Link A, Perrin J, Finke D, Luther SA (2009) Novel function for interleukin-7 in dendritic cell development. Blood 113:3961\u20133968. https:\/\/doi.org\/10.1182\/blood-2008-08-176321","journal-title":"Blood"},{"key":"4316_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02902","volume":"9","author":"JR Fergusson","year":"2018","unstructured":"Fergusson JR, Morgan MD, Bruchard M, Huitema L, Heesters BA, van Unen V, van Hamburg JP, van der Wel NN, Picavet D, Koning F, Tas SW, Anderson MS, Marioni JC, Holl\u00e4nder GA, Spits H (2018) Maturing human CD127+ CCR7+ PDL1+ dendritic cells express AIRE in the absence of tissue restricted antigens. Front Immunol 9:2902. https:\/\/doi.org\/10.3389\/fimmu.2018.02902","journal-title":"Front Immunol"},{"key":"4316_CR45","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/bmt.2013.134","volume":"49","author":"M Koyama","year":"2014","unstructured":"Koyama M, Hashimoto D, Nagafuji K, Eto T, Ohno Y, Aoyama K, Iwasaki H, Miyamoto T, Hill GR, Akashi K, Teshima T (2014) Expansion of donor-reactive host T cells in primary graft failure after allogeneic hematopoietic SCT following reduced-intensity conditioning. Bone Marrow Transplant 49:110\u2013115. https:\/\/doi.org\/10.1038\/bmt.2013.134","journal-title":"Bone Marrow Transplant"},{"key":"4316_CR46","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1084\/jem.20122571","volume":"210","author":"G Gasteiger","year":"2013","unstructured":"Gasteiger G, Hemmers S, Bos PD, Sun JC, Rudensky AY (2013) IL-2-dependent adaptive control of NK cell homeostasis. J Exp Med 210:1179\u20131187. https:\/\/doi.org\/10.1084\/jem.20122571","journal-title":"J Exp Med"},{"key":"4316_CR47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cytogfr.2020.12.003","volume":"59","author":"X Yao","year":"2021","unstructured":"Yao X, Matosevic S (2021) Chemokine networks modulating natural killer cell trafficking to solid tumors. Cytokine Growth Factor Rev 59:36\u201345. https:\/\/doi.org\/10.1016\/j.cytogfr.2020.12.003","journal-title":"Cytokine Growth Factor Rev"},{"key":"4316_CR48","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.celrep.2018.06.038","volume":"24","author":"O Schulz","year":"2018","unstructured":"Schulz O, Han\u010d P, B\u00f6ttcher JP, Hoogeboom R, Diebold SS, Tolar P, Reis e Sousa C (2018) Myosin II synergizes with F-actin to promote DNGR-1-dependent cross-presentation of dead cell-associated antigens. Cell Rep 24:419\u2013428. https:\/\/doi.org\/10.1016\/j.celrep.2018.06.038","journal-title":"Cell Rep"},{"key":"4316_CR49","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41590-020-00824-x","volume":"22","author":"J Canton","year":"2021","unstructured":"Canton J, Blees H, Henry CM, Buck MD, Schulz O, Rogers NC, Childs E, Zelenay S, Rhys H, Domart MC, Collinson L, Alloatti A, Ellison CJ, Amigorena S, Papayannopoulos V, Thomas DC, Randow F, Reis e Sousa C (2021) The receptor DNGR-1 signals for phagosomal rupture to promote cross-presentation of dead-cell-associated antigens. Nat Immunol 22:140\u2013153. https:\/\/doi.org\/10.1038\/s41590-020-00824-x","journal-title":"Nat Immunol"},{"key":"4316_CR50","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1016\/j.cell.2021.05.021","volume":"184","author":"E Giampazolias","year":"2021","unstructured":"Giampazolias E, Schulz O, Lim KHJ, Rogers NC, Chakravarty P, Srinivasan N, Gordon O, Cardoso A, Buck MD, Poirier EZ, Canton J, Zelenay S, Sammicheli S, Moncaut N, Varsani-Brown S, Rosewell I, Reis e Sousa C (2021) Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity. Cell 184:4016-4031.e4022. https:\/\/doi.org\/10.1016\/j.cell.2021.05.021","journal-title":"Cell"},{"key":"4316_CR51","doi-asserted-by":"publisher","first-page":"12569","DOI":"10.1002\/cam4.5907","volume":"12","author":"T Sasaki","year":"2023","unstructured":"Sasaki T, Sakoda Y, Adachi K, Tokunaga Y, Tamada K (2023) Therapeutic effects of anti-GM2 CAR-T cells expressing IL-7 and CCL19 for GM2-positive solid cancer in xenograft model. Cancer Med 12:12569\u201312580. https:\/\/doi.org\/10.1002\/cam4.5907","journal-title":"Cancer Med"},{"key":"4316_CR52","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1158\/2767-9764.Crc-24-0226","volume":"4","author":"K Ohta","year":"2024","unstructured":"Ohta K, Sakoda Y, Adachi K, Shinozaki T, Nakajima M, Yasuda H, Nagano H, Tamada K (2024) Therapeutic efficacy of IL7\/CCL19-expressing CAR-T cells in intractable solid tumor models of glioblastoma and pancreatic cancer. Cancer Res Commun 4:2514\u20132524. https:\/\/doi.org\/10.1158\/2767-9764.Crc-24-0226","journal-title":"Cancer Res Commun"},{"key":"4316_CR53","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.coviro.2015.05.002","volume":"13","author":"ME Karpel","year":"2015","unstructured":"Karpel ME, Boutwell CL, Allen TM (2015) BLT humanized mice as a small animal model of HIV infection. Curr Opin Virol 13:75\u201380. https:\/\/doi.org\/10.1016\/j.coviro.2015.05.002","journal-title":"Curr Opin Virol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04316-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04316-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04316-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T06:58:17Z","timestamp":1770447497000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04316-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":53,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["4316"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04316-z","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Koji Tamada holds a position of director in Noile-Immune Biotech Inc. Yukimi Sakoda serves as an advisor of Noile-Immune Biotech Inc. Koji Tamada and Yukimi Sakoda are shareholders of Noile-Immune Biotech Inc. and receive compensation from the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal experiments were conducted in compliance with national regulations for the ethical care and use of laboratory animals and received approval from the Institutional Animal Care and Use Committee (IACUC) of Yamaguchi University (Committee on the Ethics of Animal Experiments; protocols 14-001, 14-003, and 14-S02). All animal experiments were conducted in accordance with the ARRIVE guidelines. No human-derived materials were employed in this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"68"}}